Summary of Key Points
Recently, the "de-animalization" of new drug development has become a focal point in the industry: on one hand, the soaring prices of experimental monkeys have increased concerns about the cost of innovative drugs; on the other hand, the National Medical Products Administration (NMPA) of China's Center for Drug Evaluation (CDE) has launched the "Pioneer Program" to promote the use of new methods (Non-Animal Methods, NAMs) such as organoids and organ-on-chip technologies to replace animal experiments. Animal experiments are characterized by long cycles, high costs, and a low predictive accuracy for human reactions (only 50%-65%), while NAMs can address these shortcomings. The industry (leading CROs, organoid companies, AI pharmaceutical companies) has begun to transition and make initial commercial progress, but challenges such as inconsistent validation standards and model limitations remain key issues. Future regulatory frameworks and international recognition will determine whether NAMs can evolve from being an "efficiency tool" to a "decision-making tool."
1. Soaring Monkey Prices and Policy Initiatives Trigger Interest in De-Animalization
The recent surge in monkey prices has caused significant headaches for innovative drug companies. Large molecule drugs, such as antibodies and ADCs, require extensive monkey testing, and the increased cost of monkeys has even surpassed the expenses for early clinical trials, putting immense pressure on these firms. Meanwhile, CDE's "Pioneer Program" has provided reassurance to the industry by explicitly supporting the adoption of NAMs (including organoids and organ-on-chip technologies), marking the first time regulatory authorities have endorsed new methods to replace animal experiments.
Why now? The problems with traditional animal experiments are too evident: they are slow, expensive, and limited in sample size; moreover, there is a significant difference between animal species, meaning drugs that work well on animals may be ineffective or even toxic in humans (for example, liver toxicity, which is often missed in animal tests). With the global push for the 3R principles of "reducing, optimizing, and replacing" animal experiments, China's policy aligns with international trends and helps companies reduce costs and improve efficiency.
2. What Are NAMs, and How Can They Solve Animal Experiment Issues?
NAMs are a broad term for non-animal experimental methods, including organoids (such as mini-livers and skin cultured from human cells), organ-on-chip systems (which combine multiple organoids to simulate human systems), and AI-based computational models. Their advantages are particularly evident in three areas:
1. Liver Toxicity Assessment: The FDA is already validating these methods, with domestic liver-on-chip technologies achieving an accuracy rate of 92.3%, capable of detecting liver toxicity issues missed in animal tests (for example, some drugs may be harmless to monkeys but cause liver damage in humans).
2. Local Drug Administration: For drugs used in specific body areas like the eyes or skin, organoids can more accurately simulate human tissue reactions than animal skin tests (since the structure of animal and human skin differs, leading to more reliable results).
3. Diseases Without Suitable Animal Models: For conditions like atherosclerosis and blood-brain barrier disorders, where traditional methods fail to find suitable animal models, NAMs represent the only viable option.
In short, NAMs can address issues that animal experiments cannot solve and provide more reliable results in areas where animal tests are unreliable.
3. Industry Players Accelerating Transformation
Seeing the policy momentum and market demand, various industry players have started to act:
- Leading CROs Transforming: Companies like Zhaoyan New Drug, which once profited from high monkey prices, are now investing in organoid platforms for toxicology evaluations (using brain, liver, and other organoids).
- Organoid Companies Commercializing: Shanghai Yaosu Technology expects to generate tens of millions in revenue by 2026 and has signed long-term agreements with companies like Sanofi and Pfizer, indicating that these technologies are becoming profitable.
- AI Pharmaceuticals Joining the Scene: Companies like Yingsi Intelligence are developing automated liver organoid screening platforms using AI to analyze data and predict drug risks more accurately.
The current trend is a collaboration among CROs, organoid companies, and AI firms, working together to integrate multiple models (animals, organoids, and AI) for more comprehensive evaluations.
4. Commercialization Is Possible, but Validation Is the Barrier
Although organoid companies have already received orders, the widespread adoption of NAMs to replace animal experiments still faces challenges in validation:
1. Model Limitations: Organoids lack vascular, neural, and immune microenvironments, making it difficult to simulate overall bodily reactions (for example, a drug may be beneficial for the liver but harmful to the heart).
2. Inconsistent Regulatory Standards: Different countries have varying acceptance levels for NAMs data, and companies are concerned that using NAMs might require additional animal tests, deterring long-term investment.
3. AI’s Role: While AI can analyze data, it cannot guarantee drug efficacy and safety; predicting toxicity does not necessarily mean predicting efficacy, and vice versa.
Xie Xin from Yaosu Technology emphasizes that overcoming validation barriers is more difficult than achieving commercialization.
5. The Future Depends on Regulatory Frameworks and International Recognition
CDE has included "animal experiment replacement strategies" as a priority, with plans to release guidance documents within two years. This will clarify the scenarios in which NAMs data can replace animal experiments and the required standards. International cooperation is also crucial; if China and European/American regulatory authorities recognize each other's NAMs data, companies will be able to reduce costs significantly by avoiding duplicate tests in different countries.
In summary, de-animalization is not an immediate goal, but policies, technology, and industry trends are all moving in this direction. In the future, new drug development may no longer rely on monkeys but instead utilize more efficient and accurate organoid and AI models, marking a revolution in research and development paradigms.